Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Exact Therapeutics ASFRA:56F +16.36%22 Equity-to-Asset is 0.46 as of Dec. 2025, which is 42% below its 10-year median of 0.79. GuruFocus rates FRA:56F with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Exact Therapeutics AS ranks worse than 69.61% on this metric.
Exact Therapeutics AS (FRA:56F) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Exact Therapeutics AS Equity-to-Asset Related Terms
Exact Therapeutics AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Exact Therapeutics AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:56F vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Exact Therapeutics AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Therapeutics AS Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Exact Therapeutics AS's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Exact Therapeutics AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Therapeutics AS (FRA:56F) has a Equity-to-Asset of 0.46 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Exact Therapeutics AS and its competitors. This is 42% below median its historical median of 0.79. Over the past decade, Exact Therapeutics AS's Equity-to-Asset has ranged from 0.42 to 0.94. According to the industry distribution chart, Exact Therapeutics AS ranks #985 out of 1415 companies in the Biotechnology industry, placing it in the top 69.6%.
Is Exact Therapeutics AS's Equity-to-Asset too high?
Exact Therapeutics AS's current Equity-to-Asset of 0.46 is 42% below median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 0.94. The Biotechnology industry median Equity-to-Asset is 0.68. Exact Therapeutics AS's value of 0.46 is 32.4% below this industry median. Based on the distribution chart, Exact Therapeutics AS ranks #985 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Exact Therapeutics AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Exact Therapeutics AS ranks #985 out of 1415 companies for Equity-to-Asset. This places Exact Therapeutics AS in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Exact Therapeutics AS's value of 0.46 is 32.4% below this benchmark. Historically, Exact Therapeutics AS's own Equity-to-Asset has ranged from 0.42 to 0.94 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.68, Exact Therapeutics AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exact Therapeutics AS's current Equity-to-Asset of 0.46 is 32.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Exact Therapeutics AS and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exact Therapeutics AS's current Equity-to-Asset is 0.46, which is 42% below median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (FRA:56F) has a current Equity-to-Asset of 0.46. The current Equity-to-Asset is 0.46, which is 42% below median its 10-year median of 0.79 and 32.4% below the Biotechnology industry median of 0.68. Exact Therapeutics AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Exact Therapeutics AS (FRA:56F), the current Equity-to-Asset is 0.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
22GF Score
Get the complete analysis for FRA:56F
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:56F has been successfully added to your 
